Opdivo plus chemo in sufferers with superior gastric or esophageal cancers confirmed improved 5-year general survival in comparison with chemotherapy alone.Amongst sufferers with...
SHR-1701 plus chemo suppressed chemo-associated myelosuppression in HER2-negative gastric or GEJ adenocarcinoma.Amongst sufferers with HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, the...
Afinitor plus Somatuline considerably improved progression-free survival in comparison with Afinitor alone in sufferers with much less aggressive neuroendocrine tumors.Amongst sufferers with unresectable...
